Evidence map›Paper›PMID 39810890›Full record

ReviewEJIFCC2024

MicroRNA Significance in Cancer: An Updated Review on Diagnostic, Prognostic, and Therapeutic Perspectives.

Vijay Singh, Aniruddha Sen, Sapna Saini, Shailendra Dwivedi, Ruchika Agrawal, Akash Bansal, Shashank Shekhar

Abstract readReview
In one paragraph

Review in EJIFCC, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vijay SinghDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, 273008, India.
Aniruddha SenDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, 273008, India.
Sapna SainiDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, 273008, India.
Shailendra DwivediDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, 273008, India.
Ruchika AgrawalDepartment of ENT, All India Institute of Medical Sciences Gorakhpur, 273008, India.
Akash BansalDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, 273008, India.
Shashank ShekharDepartment of Radiotherapy, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, 273008, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article provides a thorough and up-to-date analysis of the role that microRNAs (miRNAs) within the realm of cancer therapy, paying specific attention to their diagnostic, prognostic as well as therapeutic capabilities. The miRNAs (small non-coding RNAs) are the current major genes that regulate gene expression. They are a key factor in the genesis of cancer. They are oncogenes, or tumor suppressors that play key functions in the signaling pathway that contribute to the development of cancer. This article focuses on the double importance of microRNAs for cancer oncogenesis. This includes both their ability to inhibit cancer suppressor genes and the stimulation of cancer-causing oncogenes. MicroRNAs have been identified for a long time as biomarkers to help in diagnosing cancer and have distinct signatures specific to different kinds of cancer. There are many detection strategies including RT-qPCR, Next Generation Sequencing (NGS) as well as Microarray Analysis that have been evaluated to prove their effectiveness in aiding the non-invasive diagnosis of cancer. The paper provides an overview of the importance of miRNAs to prognosis, highlighting their ability to forecast tumor progression as well as outcomes for cancer patients. In addition, their therapeutic value remains a subject of research. Research is being conducted in order to investigate miRNA-targeting therapy including antisense oligonucleotides, or small molecules inhibitors as possible treatment options for cancer. These methods could favor more specific and individualized approaches than the current techniques. The article also focuses on the current challenges and future prospects linked to miRNA research and demonstrates the complex biological functions they play as well as clinical applications that require investigation. The review is the source of information for researchers, clinicians and scientists who are interested in advancing studies into cancer research as well as personalized treatments.

Indexed as

Antisense Oligonucleotides (ASOs)CancerMicroarraymicroRNA(miRNA)Next Generation Sequencing (NGS)Polymerase Chain Reaction (PCR)Tumor-Suppressor Genes

Identifiers

PMID39810890
PMCPMC11726331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.